Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS: We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either ATRA plus arsenic trioxide for induction and consolidation therapy or standard ATRA-idarubicin induction therapy followed by three cycles of consolidation therapy with ATRA plus chemotherapy and maintenance therapy with low-dose chemotherapy and ATRA. The study was designed as a noninferiority trial to show that the difference between the rates of event-free survival at 2 years in the two groups was not greater than 5%. RESULTS: Complete remission was achieved in all 77 patients in the ATRA-arsenic trioxide group who could be evaluated (100%) and in 75 of 79 patients in the ATRA-chemotherapy group (95%) (P=0.12). The median follow-up was 34.4 months. Two-year event-free survival rates were 97% in the ATRA-arsenic trioxide group and 86% in the ATRA-chemotherapy group (95% confidence interval for the difference, 2 to 22 percentage points; P<0.001 for noninferiority and P=0.02 for superiority of ATRA-arsenic trioxide). Overall survival was also better with ATRA-arsenic trioxide (P=0.02). As compared with ATRA-chemotherapy, ATRA-arsenic trioxide was associated with less hematologic toxicity and fewer infections but with more hepatic toxicity. CONCLUSIONS: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL. (Funded by Associazione Italiana contro le Leucemie and others; ClinicalTrials.gov number, NCT00482833.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Self-citationShen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
van Dongen, J., Macintyre, E., Gabert, J., Delabesse, E., Rossi, V, Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401592 · Cited by 1,169
Self-citationSanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationUnited States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826 · cited 1×
“A genetic diagnosis could be established by detection of the PML-RARA fusion gene by means of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay,28,29 demonstration of the t(15;17) translocation by means of conventional karyotyping or fluorescence in situ hybridization (FISH),30 or evidence of a microspeck…”
Research works printed but not linked: 3
- Zhang P, 1996, Chin J Hematol, 17, 58
- Sanz MA, 2000, Blood, 96, 1247
- Grimwade D, 2000, Blood, 96, 1297
Cited by
Items 401–500 of 1,000
An, K., Xue, M., Zhong, J., Yu, S., Lan, T., Qi, Z., & Xia, J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01829-x · Cited by 28
“have shown that the hepatotoxicity is usually reversible and may be successfully managed with the temporary cessation of or a decrease in ATO; there have been no reports of fatal hepatic failure in clinical trials [41, 42].”
BackgroundHamidou, M. A., Néel, A., Poupon, J., Amoura, Z., Ebbo, M., Sibilia, J., Viallard, J., Gaborit, B. J., Volteau, C., Hardouin, J.-B., et al. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02454-6 · Cited by 27
“5 mg/d and well-tolerated standard maintenance dosages of immunosuppressive drugs and approved biologics [27].”
BackgroundZhu, H., Ma, Y., Kang, Y., Ouyang, G., Luo, W., Pei, R., Xu, W., Hu, H.-X., Mo, S.-P., Xu, X., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.762653 · Cited by 28
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia
Ma, Y., Lu, Y., Wu, Q., Lou, Y., Yang, M., Xu, J., Sun, C., Mao, L., Xu, G., Li, L., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01368-3 · Cited by 27
Marchwicka, A., Cebrat, M., Łaszkiewicz, A., Śnieżewski, Ł., Brown, G., & Marcinkowska, E. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.013 · Cited by 28
Tomlinson, B. K., & Lazarus, H. M. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1326811 · Cited by 27
“With the exception of acute promyelocytic leukemia (APL), long-term survival rates for AML have not improved significantly in the past three decades [1,2].”
BackgroundBoutas, I., Potiris, A., Brenner, W., Lebrecht, A., Hasenburg, A., Kalantaridou, S., & Schmidt, M. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05292-9 · Cited by 27
“Arsenic trioxide is an inorganic compound that can inhibit tumor growth and induce apoptosis in many cancers such us acute promyelocytic leukemia and breast [34, 35].”
BackgroundAcute myeloid leukemia: challenges for diagnosis and treatment in Latin America
León, A. G., Demichelis‐Gómez, R., Costa, A., Gómez‐Almaguer, D., & Rego, E. M. (2023) · Hematology · doi:10.1080/16078454.2022.2158015 · Cited by 30
“After a median follow-up of 40.6 months, EFS, CIR, and 50-month OS for patients in the ATRA-ATO versus ATRA-chemotherapy arms were 97.3% vs 80%, 1.9% vs 13.9% and 99.2% vs 92.6%, respectively with signi fi cant di ff erences [120,121].”
BackgroundMethodInfluentialGhiaur, A. E., Doran, C., Găman, M., Ionescu, B. O., Tatic, A., Cirstea, M., Stancioaica, C., Hirjan, R., & Coriu, D. (2024) · Cancers · doi:10.3390/cancers16061160 · Cited by 26
Tan, Y., Qin, S., Zhang, Z., Liu, Y., Zhou, L., Li, B., Nice, E. C., Zhang, Y., & Jing, J. (2025) · MedComm – Oncology · doi:10.1002/mog2.70009 · Cited by 32
Hassani, S., Khaleghian, A., Ahmadian, S., Alizadeh, S., Alimoghaddam, K., Ghavamzadeh, A., & Ghaffari, S. H. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3163-y · Cited by 27
Yoon, J., Kim, H., Min, G. J., Park, S., Jeon, Y., Lee, S., Cho, B., Eom, K., Kim, Y., Lee, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47937-4 · Cited by 26
Zhu, S., Liu, X., Xue, M., Li, Y., Cai, D., Wang, S., & Zhang, L. (2020) · Journal of Ginseng Research · doi:10.1016/j.jgr.2020.05.001 · Cited by 26
“severely affect patients' life quality [11].”
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children
Pearson, A. D. J., Stegmaier, K., Bourdeaut, F., Reaman, G. H., Heenen, D. L., Meyers, M. L., Armstrong, S. A., Brown, P. A., Carvalho, D. D. D., Jabado, N., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.08.014 · Cited by 26
Tao, S., Song, L., Deng, Y., Chen, Y., Shi, Y., Gan, Y., Deng, Z.-K., Ding, B., He, Z., Wang, C., et al. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s273172 · Cited by 26
Shams, A. M., Binothman, N., Boudreault, J., Wang, N., Shams, F., Hamam, D., Tian, J., Moamer, A., Dai, M., Lebrun, J. J., et al. (2021) · Oncogenesis · doi:10.1038/s41389-020-00297-5 · Cited by 31
Dhakal, P., Lyden, E. R., Rajasurya, V., Zeidan, A. M., Chaulagain, C. P., Gundabolu, K., & Bhatt, V. R. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1894651 · Cited by 27
Arsenic trioxide-induced cardiotoxicity triggers ferroptosis in cardiomyoblast cells
Wang, L., Liu, S., Gao, C., Chen, H., Li, J., Lu, J., Yuan, Y., Zheng, X., He, H., Zhang, X., et al. (2022) · Human & Experimental Toxicology · doi:10.1177/09603271211064537 · Cited by 26
Renu, K., Mukherjee, A. G., Gopalakrishnan, A. V., Wanjari, U. R., Kannampuzha, S., Murali, R., Veeraraghavan, V. P., Vinayagam, S., Paz, S., George, A., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126715 · Cited by 27
Ravandi, F., Cloos, J. J., Buccisano, F., Dillon, R. J., Döhner, K., Freeman, S. D., Hourigan, C. S., Ossenkoppele, G. J., Roboz, G. J., Subklewe, M., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27087 · Cited by 30
Self-citationKlobuch, S., Steinberg, T., Bruni, E., Mirbeth, C., Heilmeier, B., Ghibelli, L., Herr, W., Reichle, A., & Thomas, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01380 · Cited by 29
Liu, Z., Han, J., Su, S., Zeng, Q., Wu, Z., Yuan, J., & Yang, J. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116887 · Cited by 25
MicroRNAs in Myeloid Hematological Malignancies
Ciccone, M., & Călin, G. A. (2015) · Current Genomics · doi:10.2174/138920291605150710122815 · Cited by 25
“The backbone of treatment for patients with APL includes all-trans retinoic acid (ATRA) in combination with trioxide arsenic (ATO) or antracyclinebased chemotherapy.”
BackgroundOral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia
Lou, Y., Ma, Y., Jin, J., & Zhu, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.597601 · Cited by 25
“In 2013, the landmark APL0406 trial demonstrated the superior efficacy, safety and quality of life for ATO-ATRA in comparison with the ATRA plus chemotherapy regimen in non-high risk APL patients (27, 28).”
Arteaga, M. F., Mikesch, J.-H., Fung, T.-K., & So, C. W. E. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.374 · Cited by 28
“1Leukaemia and Stem Cell Biology Group, Department of Haematological Medicine, King’s College London, Denmark Hill,”
BackgroundNoguera, N. I., Piredda, M. L., Taulli, R., Catalano, G., Angelini, G., Gaur, G., Nervi, C., Voso, M. T., Lunardi, A., Pandolfi, P. P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11964 · Cited by 27
Self-citationAnalysis of Clinical Profile and Outcome of Tuberculosis in Patients with Acute Leukemia
Jain, A., Prakash, G., Singh, C., Lad, D. P., Khadwal, A., Suri, V., Malhotra, P., Kumari, S., Varma, N., & Varma, S. C. (2017) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-017-0875-z · Cited by 25
“Although the use of this chemotherapy free regime has decreased the rates of bacterial and fungal infections however the incidence of Tuberculosis in patients treated on ATO/ATRA regime remains undetermined [20].”
Cicconi, L., Breccia, M., Franceschini, L., Latagliata, R., Molica, M., Divona, M., Diverio, D., Rizzo, M., Ottone, T., Iaccarino, L., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3400-z · Cited by 25
Self-citationThe Role of Forkhead Box Proteins in Acute Myeloid Leukemia
Gurnari, C., Falconi, G., Bellis, E. D., Voso, M. T., & Fabiani, E. (2019) · Cancers · doi:10.3390/cancers11060865 · Cited by 29
“Arsenic trioxide in combination with ATRA is currently considered the standard of care for adults with low-to-intermediate-risk APL, with a complete remission rate near to 100% [54].”
BackgroundMaghmomeh, A. O., El-Gayar, A. M., El-Karef, A. A., & Abdel‐Rahman, N. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01734-y · Cited by 27
Zhang, Z., Jiang, M. P., Borthakur, G. M., Luan, S., Huang, X., Tang, G., Xu, Q., Ji, D., Boyer, A. D., Li, F., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25689 · Cited by 25
“To the Editor: Acute promyelocytic leukemia (APL) is characterized by the PMLRARA fusion gene, which is generated by chromosomal translocation t(15;17) (q22;q21), and can be induced differentiation by all-trans retinoic acid (ATRA) and arsenic.(1) However, occasional acute myeloid leukemia (AML) cases with classic mor…”
BackgroundJillella, A. P., Arellano, M. L., Gaddh, M., Langston, A. A., Heffner, L. T., Winton, E. F., McLemore, M. L., Zhang, C., Caprara, C. R., Simon, K. S., et al. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00395 · Cited by 27
“Hyperleukocytosis was managed with hydroxyurea and rarely with chemotherapy per published studies.(6) Patients were weighed at admission on a standing bedside scale, and aggressive diuresis was used to maintain patients at baseline weight.”
MethodZassadowski, F., Pokorná, K., Ferré, N., Guidez, F., Llopis, L., Chourbagi, O., Chopin, M., Poupon, J., Fenaux, P., Padua, R. A., et al. (2015) · Leukemia · doi:10.1038/leu.2015.159 · Cited by 24
Targeting the mitochondria in acute myeloid leukemia
Mendoza, S. E. S., & Rego, E. M. (2017) · Applied cancer research/Applied Cancer Research · doi:10.1186/s41241-017-0022-z · Cited by 24
Efficace, F., Breccia, M., Avvisati, G., Cottone, F., Intermesoli, T., Borlenghi, E., Carluccio, P., Rodeghiero, F., Fabbiano, F., Luppi, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0325-4 · Cited by 26
“ATRA and chemotherapy was the standard of care until very recently, when two pivotal randomized controlled trials (RCTs) showed significantly better treatment efficacy and safety with arsenic trioxide (ATO) in combination with ATRA versus standard ATRA plus chemotherapy for at least patients with non-high-risk APL [8,…”
BackgroundSelf-citationOld dog, new trick: Trivalent arsenic as an immunomodulatory drug
Ye, Y., Gaugler, B., Mohty, M., & Malard, F. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15011 · Cited by 24
“…acid (ATRA), has revolutionized the treatment of APL: The outcome changed from 35% to 45% long-term overall survival by chemotherapy to a complete remission rate of over 95% and a long-term survival rate up to 90% with a chemotherapy free approach (Cicconi & Lo-Coco, 2016; Lo-Coco et al., 2013).”
BackgroundMethodInfluentialSong, Z., Zhang, J., Xu, Q., Shi, D., Yao, X., & Fang, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01441 · Cited by 25
Padinharayil, H., Rai, V., & George, A. (2023) · Cancers · doi:10.3390/cancers15041070 · Cited by 30
The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA
Jaffray, E., Tatham, M. H., Mojsa, B., Liczmańska, M., Rojas‐Fernández, A., Yin, Y., Ball, G., & Hay, R. T. (2023) · The Journal of Cell Biology · doi:10.1083/jcb.202201027 · Cited by 27
de Assis, P. A., de Figueiredo‐Pontes, L. L., de Lima, A. S. G., Leão, V., Cândido, L. A., Pintão, C. T., Garcia, A. B., Saggioro, F. P., Panepucci, R. A., Chahud, F., et al. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0181-2 · Cited by 24
“Thus, associations of ATRA with chemotherapy or arsenic trioxide have been more successful in improve long-term survival [19].”
Lou, Y., Suo, S., Tong, H., Ye, X., Wang, Y., Chen, Z., Qian, W., Meng, H., Mai, W., Huang, J. B., et al. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.07.030 · Cited by 24
Oral targeted therapy for cancer
Carrington, C. (2015) · Australian Prescriber · doi:10.18773/austprescr.2015.060 · Cited by 31
Song, Y.-H., Peng, P., Qiao, C., Zhang, R., Li, J., & Lu, H. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s144438 · Cited by 24
“However, the ATRA + ATO regimen alone may be inadequate for high-risk patients.(24,25) New immunotherapies such as CD33 monoclonal antibodies may be a viable method for better reducing the incidence of severe bleeding in APL.”
BackgroundJiang, X., Chen, C., Gu, S., & Zhang, Z. (2017) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2017.12.011 · Cited by 25
Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis
Heudobler, D., Rechenmacher, M., Lüke, F., Vogelhuber, M., Klobuch, S., Thomas, S., Pukrop, T., Hackl, C., Herr, W., Ghibelli, L., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01357 · Cited by 24
“, 2010; Iland and Seymour, 2013) but both drugs are commonly administered combined with transcriptional modulators, alltrans-retinoic acid and dexamethasone, respectively (Lo-Coco et al., 2013; Benboubker et al., 2014).”
BackgroundAcute promyelocytic leukemia and variant fusion proteins: PLZF-RARα fusion protein at a glance
Hussain, L., Maimaitiyiming, Y., Islam, K., & Naranmandura, H. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.04.004 · Cited by 24
Lucena-Araujo, A. R., Coelho‐Silva, J. L., Pereira‐Martins, D. A., Silveira, D. R., Koury, L. C. A., Melo, R. A. M., Bittencourt, R., Pagnano, K. B. B., Pasqüini, R., Nunes, E. C., et al. (2019) · Blood · doi:10.1182/blood.2019000239 · Cited by 24
Self-citationRole of mitochondria and cardiolipins in growth inhibition of breast cancer cells by retinoic acid
Terao, M., Goracci, L., Celestini, V., Kurosaki, M., Bolis, M., Veroli, A. D., Vallerga, A., Fratelli, M., Lupi, M., Corbelli, A., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1438-y · Cited by 29
Lin, X.-J., Qiao, N., Shen, Y., Fang, H., Xue, Q., Cui, B., Chen, L., Zhu, H., Zhang, S., Chen, Y., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4375 · Cited by 26
Käyser, S., Schlenk, R. F., Lebon, D., Carré, M., Götze, K. S. S., Stölzel, F., Berceanu, A., Schäfer‐Eckart, K., Péterlin, P., Hicheri, Y., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278722 · Cited by 25
“02).(2) Within this trial, the early mortality rate as well as hematologic toxicities were significantly lower in patients treated with ATO/ATRA than in those treated with AIDA.”
BackgroundMethodResultInfluentialSelf-citationCampione, E., Gaziano, R., Doldo, E., Marino, D., Falconi, M., Iacovelli, F., Tagliaferri, D., Pacello, L., Bianchi, L., Lanna, C., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01874-20 · Cited by 23
Tallman, M. S., Lo‐Coco, F., Barnes, G., Kruse, M., Wildner, R., Martin, M., Mueller, U. W., & Tang, B. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.07.634 · Cited by 23
Self-citationSalvatorelli, E., Menna, P., Chello, M., Covino, E., & Minotti, G. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.246140 · Cited by 23
Kutny, M. A., Geyer, S. M., Laumann, K. M., Gregory, J., Willman, C. L., Stock, W., Larson, R. A., Powell, B. L., & Feusner, J. H. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27542 · Cited by 24
Retinoic Acid Reduces Stem Cell–Like Features in Pancreatic Cancer Cells
Herreros‐Villanueva, M., Er, T., & Bujanda, L. (2015) · Pancreas · doi:10.1097/mpa.0000000000000373 · Cited by 23
Treatment of Acute Promyelocytic Leukemia
Lo‐Coco, F., Orlando, S. M., & Platzbecker, U. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1309895 · Cited by 23
Self-citationWen, J., Li, A., Wang, Z., Guo, X., Zhang, G. L., Litzow, M. R., & Liu, Q. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1536388 · Cited by 24
Paroni, G., Zanetti, A., Barzago, M. M., Kurosaki, M., Guarrera, L., Fratelli, M., Troiani, M., Ubezio, P., Bolis, M., Vallerga, A., et al. (2020) · Cancers · doi:10.3390/cancers12103027 · Cited by 22
“In combination with chemotherapy or arsenic trioxide, ATRA is used in the treatment of acute promyelocytic leukemia with outstanding results, inducing long-term remission in the majority of patients [14].”
BackgroundKulkarni, U. P., Selvarajan, S., Lionel, S. A., Prakash, M. A., Palani, H. K., Balasundaram, N., Venkataraman, A., Korula, A., Devasia, A. J., Fouzia, N. A., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00619-3 · Cited by 22
Huang, D., Yang, L., Chen, Y.-Q., Wan, W., Zhou, D., Mai, H., Li, W., Yang, L.-H., Lan, H., Chen, H., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00949-w · Cited by 28
FISH-negative, cytogenetically cryptic acute promyelocytic leukemia
Rashidi, A., & Fisher, S. I. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.47 · Cited by 22
Albano, F., Zagaria, A., Anelli, L., Orsini, P., Minervini, C. F., Impera, L., Casieri, P., Coccaro, N., Tota, G., Brunetti, C., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1619 · Cited by 22
“It could therefore be useful to improve risk stratification and to develop better tailored treatment strategies in APL patients affected by LEF1 low expression [41].”
BackgroundSelf-citationLong‐term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid
Zhu, H., Wu, D., Jin, J., Li, J., Ma, J., Wang, J., Chen, S., & Huang, X. (2015) · British Journal of Haematology · doi:10.1111/bjh.13809 · Cited by 22
Targeting of leukemia-initiating cells in acute promyelocytic leukemia.
Testa, U., & Lo‐Coco, F. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2306-9759.2015.04.03 · Cited by 22
“All patients in the ATRA + ATO group achieved a complete remission, compared to 95% in the ATRA + chemotherapy group; the 2-year event-free survival rates (primary objective of the study) were 97% and 86% in the ATRA+ATO and ATRA + chemotherapy groups, respectively; overall survival was also significantly better in th…”
ResultSelf-citationTargeting prohibitins induces apoptosis in acute myeloid leukemia cells
Pomares, H., Palmeri, C. M., Iglesias‐Serret, D., Moncunill‐Massaguer, C., Saura‐Esteller, J., Núñez‐Vázquez, S., Gamundí, E., Arnán, M., Preciado, S., Alberício, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11333 · Cited by 23
“BMMNC or PBMNC from 6 samples from AML patients after relapse were incubated for 24 or 48 h with increasing doses of fluorizoline ranging from 1.25 to 20 µM.”
BackgroundInfluentialChen, M., Zhong, L., Yao, S., Zhao, Y. C., Liu, L., Li, L., Xu, T., Gan, L., Xiao, C., Shan, Z., et al. (2017) · International Journal of Medical Sciences · doi:10.7150/ijms.19682 · Cited by 24
“It was further reported that p38 MAPK regulates cell apoptosis, proliferation, and senescence [37], and that p-p38 MAPK is expressed at lower levels in AML cells than in normal hematopoietic stem cells [38].”
BackgroundInfluentialPredictive factors of fatal bleeding in acute promyelocytic leukemia
Mantha, S. H., Tallman, M. S., Devlin, S. M., & Soff, G. A. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.01.038 · Cited by 22
Nagai, K., Hou, L., Li, L., Nguyen, B., Seale, T. S., Shirley, C. M., Ma, H., Levis, M. J., Ghiaur, G., Duffield, A. S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25972 · Cited by 22
Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders
Faraoni, I., Giansanti, M., Voso, M. T., Lo‐Coco, F., & Graziani, G. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.04.019 · Cited by 24
Self-citationBewersdorf, J. P., Shallis, R. M., Boddu, P. C., Wood, B. L., Radich, J. P., Halene, S., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100650 · Cited by 24
Kulkarni, U. P., Ganesan, S., Alex, A. A., Palani, H. K., David, S., Balasundaram, N., Venkatraman, A., Mani, T., Jeyaseelan, L., Korula, A., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2883 · Cited by 23
Eide, C. A., Kurtz, S. E., Kaempf, A. J., Long, N., Agarwal, A., Tognon, C. E., Mori, M., Druker, B. J., Chang, B. H., Danilov, A. V., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0764-6 · Cited by 25
Maimaitiyiming, Y., Zhu, H., Yang, C., & Naranmandura, H. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1791173 · Cited by 23
“Strong cytotoxic chemotherapy is completely replaced by ATO in this modality of treatment (Lo-Coco et al. 2013; Zhu et al. 2018a, 2018b).”
BackgroundMethodRealgar and arsenene nanomaterials as arsenic-based anticancer agents
Hollow, S. E., & Johnstone, T. C. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102229 · Cited by 22
de Figueiredo‐Pontes, L. L., Catto, L. F. B., Chauffaille, M. D. L., Pagnano, K. B. B., Madeira, M. I. A., Nunes, E. C., Hamerschlak, N., Silva, M. C. D. A., Carneiro, T. X., Bortolheiro, T. C., et al. (2024) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2024.05.002 · Cited by 23
Jen, W., Marvin‐Peek, J., Kantarjian, H. M., Alvarado, Y., Borthakur, G. M., Jabbour, E. J., Wierda, W. G., Kadia, T. M., Daver, N. G., Dinardo, C. D., et al. (2024) · Cancer · doi:10.1002/cncr.35662 · Cited by 21
“3,6 The induction mortality in the SWOG study was 10%, and the CR rate was 86%.”
Why Is Progress in Acute Myeloid Leukemia So Slow?
Estey, E. H. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.03.007 · Cited by 21
Chen, J., Wei, H., Cheng, J. J., Xie, B., Wang, B., Yi, J., Tian, B., Liu, Z., Wang, F., & Zhang, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.7353 · Cited by 21
“…or decreased (when incubated in ADM-free media for 15-60 days), but more slowly compared with the total number of LSCs, with increasing resistance to ADM. BCRP in LSCs or leukemic CD34 + CD38 - stem cells were preferentially expressed and may contribute to their resistant phenotype (26,28,32).”
Zheng, A., Xie, F. X., Shi, S., Liu, S., Long, J., & Xu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.829391 · Cited by 24
“Oral administration of All-trans retinoic acid (ATRA) combined with chemotherapy is now the standard of care for treating Acute Promyelocytic Leukemia (APL) in adults (22).”
BackgroundGagnon, M.-F., Berg, H. E., Meyer, R. G., Sukov, W. R., Dyke, D. L. V., Jenkins, R. B., Greipp, P. T., Thorland, E. C., Hoppman, N. L., Xu, X., et al. (2022) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23070 · Cited by 21
How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy
Korsos, V., & Miller, W. H. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-22-0141 · Cited by 22
Smith, M. B., Griffiths, E. A., Thompson, J. E., Wang, E. S., Wetzler, M., & Freyer, C. W. (2014) · Leukemia Research Reports · doi:10.1016/j.lrr.2014.07.001 · Cited by 21
“The diagnosis of PTC, based on the Modified Dandy Criteria, is made when a patient exhibits an elevated LP opening pressure above 25 cm H20 with normal CSF composition and radiologic findings, and no other explanation for the rise in intracranial pressure [6].”
BackgroundMethodInfluentialSpinelli, O., Rambaldi, A., Rigo, F., Zanghì, P., D’Agostini, E., Amicarelli, G., Colotta, F., Divona, M., Ciardi, C., Lo‐Coco, F., et al. (2014) · Oncoscience · doi:10.18632/oncoscience.114 · Cited by 21
“These strategies have dramatically changed the natural history of this disease and converted APL from a highly fatal into a highly curable leukemia [14].”
BackgroundSelf-citationLG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia
Wang, X., Lin, Q., Lv, F., Liu, N., Xu, Y., Liu, M., Chen, Y., & Yi, Z. (2016) · Leukemia · doi:10.1038/leu.2016.50 · Cited by 21
Optimal treatment strategies for high-risk acute promyelocytic leukemia
Norsworthy, K. J., & Altman, J. K. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000215 · Cited by 21
“NCCN guidelines recommend prednisone from day 1 until completion of induction for ATRAþATO regimens, as in the landmark Lo-Coco study [5].”
BackgroundMethodInfluentialShu, Y., Cao, H., Wu, L.-K., Hou, G., Tang, Y., & Zheng, G. (2018) · Hydrometallurgy · doi:10.1016/j.hydromet.2018.11.006 · Cited by 21
Endogenous and combination retinoids are active in myelomonocytic leukemias
di Martino, O., Niu, H., Hadwiger, G., Kuusanmäki, H. A., Ferris, M. A., Vu, A., Beales, J. T., Wagner, C. E., Menéndez-Gutierrez, M. P., Ricote, M., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.264432 · Cited by 22
History of Acute Promyelocytic Leukemia
Sanz, M. Á., & Barragán, E. (2021) · Clinical Hematology International · doi:10.2991/chi.k.210703.001 · Cited by 23
“Two multicenter phase 3 trials were set up to compare the efficacy and safety of ATRA plus ATO versus ATRA plus chemotherapy [107,108].”
Faulk, K. E., Gore, L., & Cooper, T. M. (2014) · Pediatric Drugs · doi:10.1007/s40272-014-0067-3 · Cited by 26
Telomere length recovery: a strong predictor of overall survival in acute promyelocytic leukemia
Baljevic, M., Dumitriu, B., Lee, J.-W., Paietta, E. M., Wiernik, P. H., Racevskis, J., Chen, C., Stein, E. M., Gallagher, R. E., Rowe, J. M., et al. (2016) · Acta Haematologica · doi:10.1159/000448160 · Cited by 20
“Recently reported phase III trials from Europe that utilized the ATRA/ATO combinations upfront across all APL risk-subgroups did not explore the role of telomere dynamics in disease stratification and/or low rates of relapse[24,25].”
BackgroundNorsworthy, K. J., Avagyan, A., Bird, S. T., Li, Y., Akhtar, S., Liao, J., Wernecke, M., Deisseroth, A., Chuk, M. K., MaCurdy, T. E., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0905-y · Cited by 20
Clinical and molecular consequences of fusion genes in myeloid malignancies
Matsukawa, T., & Aplan, P. D. (2020) · Stem Cells · doi:10.1002/stem.3263 · Cited by 23
Vitamin C Deficiency in Patients With Acute Myeloid Leukemia
Ottone, T., Faraoni, I., Fucci, G., Divona, M., Travaglini, S., Bellis, E. D., Marchesi, F., Angelini, D. F., Palmieri, R., Gurnari, C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.890344 · Cited by 22
“WBC n/mcL (median, range) 8930 (10-83200) 2260 (1090-33300)”
BackgroundSelf-citationBender, O., Shoman, M. E., Ali, T. F. S., Dogan, R., Çelik, İ., Mollica, A., Hamed, M. I. A., Aly, O. M., Alamri, A., Alanazi, J., et al. (2022) · Archiv der Pharmazie · doi:10.1002/ardp.202200407 · Cited by 20
Sung, P. J., Selvam, M., Riedel, S. S., Xie, H. M., Bryant, K. M., Manning, B. S., Wertheim, G. B. W., Kulej, K., Pham, L., Bowman, R. L., et al. (2024) · Leukemia · doi:10.1038/s41375-023-02131-4 · Cited by 23
“Further promoting differentiation with FLT3i may be bene fi cial analogous to the addition of arsenic to all-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL), which increases differentiation and cures over 90% of patients with this AML subtype [16].”
Litzow, M. R., Fielding, A. K., Luger, S. M., Paietta, E. M., Ofran, Y., Rowe, J. M., Goldstone, A. H., Tallman, M. S., & Lazarus, H. M. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.110 · Cited by 20
The autophagy scaffold protein ALFY is critical for the granulocytic differentiation of AML cells
Schläfli, A. M., Isakson, P., Garattini, E., Simonsen, A., & Tschan, M. P. (2017) · Scientific Reports · doi:10.1038/s41598-017-12734-4 · Cited by 22
Zhang, L., Zou, Y., Chen, Y., Guo, Y., Yang, W., Chen, X., Wang, S., Liu, X., Ruan, M., Zhang, J., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4280-2 · Cited by 20
“The APL0406 randomized trial showed that in patients with non-highrisk APL, better outcomes were achieved in those treated with ATRA-ATO than in those treated with standard ATRA-chemotherapy [7, 8].”
BackgroundResultInfluentialUltimate Precision: Targeting Cancer but Not Normal Self-replication
Velcheti, V., Schrump, D. S., & Saunthararajah, Y. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199753 · Cited by 23
Alfonso, V., Iaccarino, L., Ottone, T., Cicconi, L., Lavorgna, S., Divona, M., Cairoli, R., Cristiano, A., Ciardi, C., Travaglini, S., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0298-3 · Cited by 20
Self-citation
Metadata
- Authors
- Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., Specchia, G., Sica, S., Divona, M., Levis, A., Fiedler, W., Cerqui, E., Breccia, M., Fioritoni, G., Salih, H. R., Cazzola, M., Melillo, L., Carella, A. M., Brandts, C. H., Morra, E., von Lilienfeld-Toal, M., Hertenstein, B., Wattad, M., Lübbert, M., Hänel, M., Schmitz, N., Link, H., Kropp, M. G., Rambaldi, A., La Nasa, G., Luppi, M., Ciceri, F., Finizio, O., Venditti, A., Fabbiano, F., Döhner, K., Sauer, M., Ganser, A., Amadori, S., Mandelli, F., Döhner, H., Ehninger, G., Schlenk, R. F., & Platzbecker, U.
- ORCID
- Avvisati, Giuseppe
- Vignetti, Marco
- Thiede, Christian
- Iacobelli, Simona
- Ferrara, Felicetto
- Fazi, Paola
- Cicconi, Laura
- Specchia, Giorgina
- Sica, Simona
- Fiedler, Walter
- Breccia, Massimo
- Salih, Helmut R.
- Cazzola, Mario
- Melillo, Lorella
- Carella, Angelo M.
- Brandts, Christian H.
- Hertenstein, Bernd
- Lübbert, Michael
- Hänel, Matthias
- Schmitz, Norbert
- Link, Hartmut
- Rambaldi, Alessandro
- Luppi, Mario
- Ciceri, Fabio
- Finizio, Olimpia
- Venditti, Adriano
- Döhner, Konstanze
- Ganser, Arnold
- Amadori, Sergio
- Döhner, Hartmut
- Ehninger, Gerhard
- Schlenk, Richard F.
- Platzbecker, Uwe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-11
- Volume
- 369
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2129338773
- Cited by
- 1,611
- References
- 42
- Citations by year
- 2026: 83 · 2025: 89 · 2024: 132 · 2023: 144 · 2022: 110 · 2021: 147 · 2020: 137 · 2019: 125 · 2018: 122 · 2017: 107 · 2016: 117 · 2015: 144 · 2014: 119 · 2013: 33
- FWCI
- 61.62
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- acute promyelocytic leukemia, all-trans retinoic acid, arsenic trioxide, idarubicin, induction therapy, consolidation therapy, maintenance therapy, event-free survival, overall survival, complete remission, hematologic toxicity, hepatotoxicity
- MeSH terms
- Arsenic Trioxide, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Arsenicals, Female, Humans, Male, Middle Aged, Neutropenia, Oxides, Thrombocytopenia, Tretinoin, Leukemia, Promyelocytic, Acute, Disease-Free Survival, Young Adult, Maintenance Chemotherapy, Induction Chemotherapy, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.